FDA grants priority review to Daiichi Sankyo & Merck’s lung cancer drug application

The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

Thermo Fisher and Singapore’s PRECISE launch major proteomics push in 100,000-person study

The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation

Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector

Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Happiest Health expands dental care footprint with its second Happiest Pearls Clinic

Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model

Orbis India Partners Meet 2026 focuses on sustainable, climate-resilient eye care

Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems

C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality

The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation

Novartis expands global push to close life-saving gaps in heart disease & cancer care by 2030

Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups

Orbicular, Apotex win tentative USFDA nod for generic Ozempic

Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection